I am the David D. Thompson Professor of Pathology, Chairman of Pathology and Laboratory Medicine at Weill Cornell Medicine (WCM); and Pathologist-in-Chief in the New York-Presbyterian-Weill Cornell Campus. For many years, I have served as a Senior Staff Pathologist at Brigham and Women’s Hospital, and Chair of the Department of Oncologic Pathology at Dana-Farber Cancer Institute. At Dana-Farber/Harvard Cancer Center, I was the PI of the prostate SPORE (co-PI S. Balk) and co-leader of the DF/HCC Prostate Program. My laboratory has been focused on metabolic alterations in prostate tumorigenesis, with a specific interest in lipid metabolism as well as on the microenvironment. We have shown that fatty acid synthase (FASN) represents an ideal target in prostate cancer. This may be therapeutically exploited with FASN inhibitors, in part by downregulating AR and its splice variants. Our approach is multidisciplinary, utilizing cell lines, orthotopic tumor xenograft, genetically engineered murine models and human tumors. We have also been at the forefront in the invention and application of novel molecular pathology techniques such as ex vivo organotypic cultures, multiplexed immunohistochemistry and in situ hybridization, advances in image analysis.